|
Daily Medical Update
Drug Eruptions
Monday, June 01, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Australasian journal of dermatology (2026) - Systematic Review
Key Findings
- All 7 SCORTEN variables were significantly associated with in-hospital mortality across 45 studies including 3467 patients.
- Elevated serum creatinine was independently associated with increased risk of death, suggesting added prognostic value beyond SCORTEN alone.
📋 Practice Implication: Use SCORTEN early in suspected SJS/TEN and pay particular attention to creatinine when deciding ICU transfer, monitoring intensity, and escalation of supportive care.
|
The Lancet. Infectious diseases (2025) - Meta-Analysis
Key Findings
- Beta-lactam allergy labels were associated with higher surgical site infection risk (OR 1.60, 95% CI 1.27-2.01) and higher rates of MDRO and Clostridioides difficile infection or colonization (OR 1.42 and 1.26).
- Reported labels were associated with longer hospital stay and higher mortality at or after 180 days, although in-hospital and 30-day mortality were not significantly increased.
📋 Practice Implication: Treat an unverified beta-lactam allergy label as a modifiable safety problem, because leaving it in place can worsen antimicrobial selection and downstream outcomes.
|
The journal of allergy and clinical immunology. In practice (2025) - Meta-Analysis
Key Findings
- Positive inpatient penicillin allergy evaluations were uncommon, with pooled positivity of 3.15% for skin testing and 1.19% for direct oral challenge.
- Among 1310 patients with negative testing, 90.7% had the penicillin allergy label removed from the electronic health record.
📋 Practice Implication: Hospital penicillin delabeling programs should be expanded, since most tested inpatients can safely lose the allergy label and regain first-line antibiotic options.
|
Infection control and hospital epidemiology (2025) - Meta-Analysis
Key Findings
- Reported beta-lactam allergy was associated with increased surgical site infection risk (RR 1.55, 95% CI 1.24-1.94) across 25 studies with 460284 patients.
- Patients receiving beta-lactam prophylaxis had lower surgical site infection risk than those receiving non-beta-lactam alternatives (RR 0.63, 95% CI 0.42-0.94), with no significant difference in length of stay or hypersensitivity reactions.
📋 Practice Implication: Before surgery, verify reported beta-lactam allergy rather than defaulting to alternative prophylaxis, because access to cefazolin-class agents appears to reduce SSI risk.
|
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2025) - Meta-Analysis
Key Findings
- One-bag rapid drug desensitization achieved a 99.7% completion rate across 4473 procedures, with severe breakthrough reactions in only 0.4% of desensitizations.
- Compared with 3-bag protocols, completion rates did not differ significantly (risk difference 0.00; P = .966), while procedural duration and complexity were reduced.
📋 Practice Implication: For patients reacting to essential chemotherapy or monoclonal antibodies, a one-bag desensitization pathway can simplify delivery without materially sacrificing safety or treatment completion.
|
|
💡
Summary
Recent evidence on drug eruptions centers on two clinically actionable themes: better triage of severe cutaneous adverse reactions and correction of inaccurate antibiotic allergy labels. In SJS/TEN, SCORTEN remains strongly associated with in-hospital mortality, with serum creatinine emerging as an added prognostic marker; elsewhere, multiple meta-analyses show that reported beta-lactam allergy labels are usually disproven on testing yet still increase surgical site infections and resistant-organism risk when left unchallenged. For oncology hypersensitivity, simplified one-bag desensitization protocols appear to preserve completion and safety while reducing operational burden.
|
|